Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients

Phase 2

• Conditions: euromyelitis optica

• Registration Number: JPRN-jRCTs051180080
• Lead Sponsor: Sekiguchi Kenji

Brief Summary

MMF was effective for preventing relapse of neuromyelitis optica spectrum disorders with concomitant half dose oral corticosteroid reduction in 7/9 (77.8%, 95%CI (0.46%, 97.3%)) patients. MMF induction ameliorated cognitive tests scores without exacerbating EDSS scores. There were no cases of discontinuation of MMF due to adverse effects.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-27
• Study Completion: 2021-08-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

Stable Neuromyelitis Optica patients with EDSS score less than 7.0 who wish to participate in this study

Exclusion Criteria

1. Patients with infection
2. Patients with pregnancy or breast-feeding
3. Patients who take any immunosuppressant other than steroid
4. patients with severe liver or kidney dysfunction
5. patients with a history of cancer within 5 years (including carcinoma in situ)
6. In addition, patients judged inappropriate by the investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified